Alliance Global Partners analyst James Molloy lowered the firm’s price target on Soligenix (SNGX) to $6 from $10 and keeps a Buy rating on the shares after the company reported recent corporate updates and clinical progress of HyBryte. The firm says its price target represents a sum-of-the-parts.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNGX: